Clinical Research Directory
Browse clinical research sites, groups, and studies.
Optimizing Anti-IL17 Antibody Therapy by Associating Fiber Supplementation to Correct Treatment-aggravated Gut Dysbiosis in Axial Spondyloarthritis - RESPOND-IL17
Sponsor: Centre Hospitalier Universitaire de Nīmes
Summary
Fiber is the main source of energy for colonic bacteria and its consumption favorably modifies the composition of the microbiota in only a few days. Their fermentation in the colon releases short-chain fatty acids (SCFAs). Clostridiales contain many strains producing SCFAs. These SCFAs can restore the intestinal barrier and promote certain anti-inflammatory cells, including regulatory T cells (Tregs), which are essential to the mechanisms in tolerance of the self. Fibers could therefore correct the intestinal abnormalities present in patients with axial spondyloarthritis (AxSpA) and aggravated by anti-IL-17 drugs and thus improve the therapeutic response to these treatments. The hypothesis is that dietary fiber will correct the dysbiosis in AxSpA patients and increase the release of SCFAs, which favorably modulate the immune response and improve AxSpA.
Official title: Optimization of Anti-IL17 Antibody Therapy by Associating Fiber Supplementation to Correct Treatment-aggravated Gut Dysbiosis in Axial Spondyloarthritis - RESPOND-IL17
Key Details
Gender
All
Age Range
18 Years - 90 Years
Study Type
INTERVENTIONAL
Enrollment
36
Start Date
2023-10-02
Completion Date
2026-12-01
Last Updated
2025-05-09
Healthy Volunteers
No
Conditions
Interventions
Daily dietary supplementation with Fibruline
Supplementation with 12 grams per day of Fibruline reconstituted with 60mL of water, once a day
Anti-IL-17 therapy
Patients in both groups will be on anti-IL-17 therapy
Locations (3)
Nîmes University Hospital
Nîmes, Gard, France
Montpellier University Hospital
Montpellier, Hérault, France
Tours Regional University Hospital (Bretonneau)
Tours, Indre-et-Loire, France